{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:42:48Z","timestamp":1788856968597,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.eprac.2024.08.005","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T19:05:20Z","timestamp":1724526320000},"page":"1038-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of Teprotumumab and Role of Human Leukocyte Antigens Markers in Patients With Thyroid Eye Disease"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7437-5604","authenticated-orcid":false,"given":"Thanh D.","family":"Hoang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remigio J.","family":"Flor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"De La Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorana","family":"Raiciulescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed K.M.","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.eprac.2024.08.005_bib1","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.eprac.2024.08.005_bib2","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.eprac.2024.08.005_bib3","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/bjophthalmol-2020-316051","article-title":"Medical treatment in thyroid eye disease in 2020","volume":"105","author":"Khong","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.eprac.2024.08.005_bib4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1055\/s-0035-1555956","article-title":"Modeling graves' orbitopathy in experimental graves' disease","volume":"47","author":"Banga","year":"2015","journal-title":"Horm Metab Res"},{"issue":"3","key":"10.1016\/j.eprac.2024.08.005_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1210\/jc.2014-3566","article-title":"Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins","volume":"100","author":"Krieger","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2024.08.005_bib6","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1172\/JCI117289","article-title":"Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts","volume":"93","author":"Grubeck-Loebenstein","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.eprac.2024.08.005_bib7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1089\/thy.2012.0007","article-title":"Genetic profiling in Graves\u2019 disease: further evidence for lack of a distinct genetic contribution to Graves\u2019 ophthalmopathy","volume":"22","author":"Yin","year":"2012","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2024.08.005_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101661","article-title":"Genetics and epigenetics of autoimmune thyroid diseases: translational implications","volume":"37","author":"Lee","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"2","key":"10.1016\/j.eprac.2024.08.005_bib9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40618-021-01663-9","article-title":"2021 update on thyroid-associated ophthalmopathy","volume":"45","author":"Neag","year":"2022","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.005_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves' orbitopathy","volume":"292","author":"Bartalena","year":"2022","journal-title":"J\u00a0Intern Med"},{"issue":"12","key":"10.1016\/j.eprac.2024.08.005_bib11","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1089\/thy.2022.0251","article-title":"Management of thyroid eye disease: a consensus statement by the American thyroid association and the European thyroid association","volume":"32","author":"Burch","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.eprac.2024.08.005_bib12","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.eprac.2024.08.005_bib13","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1210\/en.2019-00055","article-title":"Arrestin-a-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk","volume":"160","author":"Krieger","year":"2019","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.005_bib14","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1210\/jc.2011-2890","article-title":"A\u00a0stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody","volume":"97","author":"Kumar","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2024.08.005_bib15","doi-asserted-by":"crossref","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2024.08.005_bib16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.15252\/emmm.201303376","article-title":"Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease","volume":"6","author":"Bilbao","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.eprac.2024.08.005_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1742-2094-10-37","article-title":"Insulin-like growth factor 1 and 2 (IGF1, IGF2) expression in human microglia: differential regulation by inflammatory mediators","volume":"10","author":"Suh","year":"2013","journal-title":"J\u00a0Neuroinflammation"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.005_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2023","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.005_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101388","article-title":"Graves' disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.eprac.2024.08.005_bib20","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and Re-treatment: OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.eprac.2024.08.005_bib21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.08.005_bib22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1136\/bjophthalmol-2020-318314","article-title":"Improvement of asymmetric thyroid eye disease with teprotumumab","volume":"106","author":"Ugradar","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.eprac.2024.08.005_bib23","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease","volume":"36","author":"Ugradar","year":"2022","journal-title":"Eye"},{"issue":"3S","key":"10.1016\/j.eprac.2024.08.005_bib24","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1097\/IOP.0000000000001831","article-title":"Teprotumumab for dysthyroid optic neuropathy: early response to therapy","volume":"37","author":"Sears","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.eprac.2024.08.005_bib25","article-title":"Early experience with teprotumumab for chronic thyroid eye disease","volume":"19","author":"Ozzello","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.005_bib26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/01676830.2021.1933081","article-title":"Teprotumumab for chronic thyroid eye disease","volume":"41","author":"Ozzello","year":"2022","journal-title":"Orbit"},{"issue":"6","key":"10.1016\/j.eprac.2024.08.005_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/IOP.0000000000001959","article-title":"Early experience with the clinical use of teprotumumab in a heterogenous thyroid eye disease population","volume":"37","author":"Diniz","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.eprac.2024.08.005_bib28","article-title":"Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: a report of two cases","volume":"22","author":"Chiou","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"2","key":"10.1016\/j.eprac.2024.08.005_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/01676830.2020.1846761","article-title":"Retinal vascularity, nerve fiber, and ganglion cell layer thickness in thyroid eye disease on optical coherence tomography angiography","volume":"41","author":"Dave","year":"2022","journal-title":"Orbit"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.005_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41433-021-01453-w","article-title":"The changes of retinal nerve fibre layer and ganglion cell layer with different severity of thyroid eye disease","volume":"36","author":"Guo","year":"2022","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.eprac.2024.08.005_bib31","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/01676830.2017.1314510","article-title":"Patterns of visual field changes in thyroid eye disease","volume":"36","author":"Choi","year":"2017","journal-title":"Orbit"},{"issue":"3","key":"10.1016\/j.eprac.2024.08.005_bib32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/eye.2012.284","article-title":"Acute thyroid eye disease (TED): principles of medical and surgical management","volume":"27","author":"Verity","year":"2013","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.005_bib33","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13256-022-03375-x","article-title":"Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series","volume":"16","author":"Chu","year":"2022","journal-title":"J\u00a0Med Case Rep"},{"issue":"10","key":"10.1016\/j.eprac.2024.08.005_bib34","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0161-6420(91)32100-6","article-title":"The role of increased intraocular pressure on upgaze in the assessment of Graves ophthalmopathy","volume":"98","author":"Spierer","year":"1991","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.eprac.2024.08.005_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242153","article-title":"Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease","volume":"14","author":"Hoang","year":"2021","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.eprac.2024.08.005_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","article-title":"Hearing dysfunction after treatment with teprotumumab for thyroid eye disease","volume":"240","author":"Sears","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.eprac.2024.08.005_bib37","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/cen.12640","article-title":"The association of thyroid peroxidase antibody risk loci with susceptibility to and phenotype of Graves\u2019 disease","volume":"83","author":"Ku\u015b","year":"2015","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.eprac.2024.08.005_bib38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/jhg.2016.135","article-title":"Gender-dependent and age-of-onset-specific association of the rs11675434 single-nucleotide polymorphism near TPO with susceptibility to Graves\u2019 ophthalmopathy","volume":"62","author":"Ku\u015b","year":"2017","journal-title":"J\u00a0Hum Genet"},{"issue":"7","key":"10.1016\/j.eprac.2024.08.005_bib39","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1167\/iovs.15-18797","article-title":"Association of polymorphisms in MACRO domain containing 2 with thyroid-associated orbitopathy","volume":"57","author":"Khong","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.eprac.2024.08.005_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41435-023-00193-z","article-title":"Significance of HLA in the development of Graves' orbitopathy","volume":"24","author":"Stasiak","year":"2023","journal-title":"Gene Immun"},{"key":"10.1016\/j.eprac.2024.08.005_bib41","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7150\/ijms.5158","article-title":"Association between HLA-B\u221746 allele and Graves\u00a0disease in Asian populations: a meta-analysis","volume":"10","author":"Li","year":"2013","journal-title":"Int J Med Sci"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24006542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:44:23Z","timestamp":1730508263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24006542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1530891X24006542"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.08.005","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Teprotumumab and Role of Human Leukocyte Antigens Markers in Patients With Thyroid Eye Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}